Davis Polk advised the underwriters in connection with the offering of $2 billion aggregate principal amount of 1.300% bonds due July 22, 2030, issued by the Province of Alberta.
The…
Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Norwegian Cruise Line Holdings Ltd. (“NCLH”) of 19,166,667 of its ordinary…
Davis Polk also advised the representatives of the initial purchasers in connection with a concurrent Rule 144A offering by NCL Corporation Ltd. (“NCLC”) of $400 million aggregate…
Davis Polk also advised the representative of the initial purchasers in connection with a concurrent Rule 144A/Regulation S offering by NCL Corporation Ltd. (“NCLC”) of $750 million…
Davis Polk advised the joint book-running managers and the initial purchasers in Rule 144A/Regulation S offerings of €325 million principal amount of 2.750% senior secured notes due 2028…
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…
Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.75 billion aggregate principal amount of its 0.750% senior notes due 2023 and (ii) $1 billion…
Davis Polk advised the underwriters on an SEC-registered offering by BankUnited, Inc. of $300 million aggregate principal amount of 5.125% subordinated notes due 2030.BankUnited, Inc…
Davis Polk advised the representatives of the several underwriters, in connection with the $1.925 billion initial public offering of 77,000,000 shares of Class A common stock of Warner…